Catalyst
Slingshot members are tracking this event:
Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
RIGL | Community voting in process |
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 01, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fit Phase 3 Program, Fostamatinib, Itp, Immune Thromboycytopenic Purpura, Oral Spleen Tyrosine Kinase, Syk